Allurkar Soumya, Patadiya Hiren Hansraj, Marmat Himani, Kundu Debapriya, Tulsi Satinder Pal Singh, Gupta Satya Prakash
Department Oral and Maxillofacial Surgery, PMNM Dental College and Hospital, Bagalkot, Karnataka, India.
Dental Practice, My Dental Southbridge, 305 Main st Southbridge, MA, USA-01550.
Bioinformation. 2025 Jan 31;21(1):44-47. doi: 10.6026/973206300210044. eCollection 2025.
Evaluation of survival outcomes and response rates among patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) treated with checkpoint inhibitors is of interest. Data regarding overall survival (OS), progression free survival (PFS), response rate, PD-L1 combined positive score (CPS) was retrieved. A total of 412 patients with histo-pathologically confirmed recurrent or metastatic HNSCC who received checkpoint inhibitor (CPI) treatment were ultimately included as members of the cohort. The median overall survival was 13.1 months. Median PFS was 4.1 months. The estimated 1-year overall survival was 53.9% while estimated 1-year PFS was 9.7%. Thus, the use of CPI therapies for first - or second-line treatment of recurrent or metastatic head and neck squamous cell carcinoma is shown.
对接受检查点抑制剂治疗的复发或转移性头颈部鳞状细胞癌（HNSCC）患者的生存结果和缓解率进行评估具有重要意义。检索了有关总生存期（OS）、无进展生存期（PFS）、缓解率、PD-L1联合阳性评分（CPS）的数据。共有412例经组织病理学确诊为复发或转移性HNSCC且接受检查点抑制剂（CPI）治疗的患者最终被纳入该队列。中位总生存期为13.1个月。中位PFS为4.1个月。估计1年总生存率为53.9%，而估计1年PFS为9.7%。因此，显示了CPI疗法用于复发或转移性头颈部鳞状细胞癌一线或二线治疗的情况。
